e-Therapeutics plc Appoints Daniel Elger as Chief Financial Officer
Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc. He joined that company in 2002 and served on its Senior Management Team from 2005, playing significant roles in corporate strategy, fundraisings and the acquisition of two US biotech companies. He also directed the investor relations strategy for the Company. Before Antisoma, Daniel was a Programme Director for major pharmaceutical companies at a leading marketing and communications agency. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.
Malcolm Young, e-Therapeutics Chief Executive said, “Daniel has a wide set of skills across corporate, financial and communications areas, and he is a valuable addition to the e-Therapeutics team. Following our £21m placing at the beginning of the year, implementing our strategic plans and communicating them to current and potential shareholders will be key elements of his role. We look forward to working with him.”
There is no other information that is required to be disclosed with regards to the above mentioned appointment pursuant to Schedule 2 paragraph (g) of the AIM Rules.
We announce the departure of Mr J.M. Cordiner from his position as Finance Director of e-Therapeutics plc and from the Board on 10 June 2011 in order to pursue other business interests. Oliver James, Non-Executive Chairman of e-Therapeutics said: "e-Therapeutics thanks Johnny for his services and wishes him well in his new business ventures."
For more information, please contact:
e-Therapeutics plc
Malcolm Young, CEO
Daniel Elger, CFO
Tel: +44 (0) 191 233 1317
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Andrew Burnett / Aubrey Powell
Tel: +44 (0) 20 7459 3600
www.panmure.com
College Hill
Melanie Toyne Sewell/Jayne Crook
Tel: +44 (0) 20 7457 2020
Email: e-therapeutics@collegehill.com
About e-Therapeutics
e-Therapeutics is a pioneering network pharmacology company focused on drug discovery and development. e-Therapeutics has a broad clinical pipeline that combines mid- and late-stage pharmaceutical products with earlier stage opportunities, all addressing important market sectors and unmet medical needs. e-Therapeutics’ novel discovery and de-risking platform is becoming increasingly well validated, demonstrating far higher productivity than conventional platforms and enabling e-Therapeutics to continue to deliver many valuable new development candidates to its portfolio. e-Therapeutics, which has a strong IP position, is focused on the progression of its drug development programmes, securing strategically important licensing partners and broadening its pipeline with new, de-risked drug candidates.
Network pharmacology is a new paradigm in drug discovery. It is based on an accurate view of the interaction of drug molecules with networks of proteins inside and between cells. It uses information on these protein networks in diseased and normal cells; information about the full range of proteins that are affected by the presence of a molecule; and a validated computational technique to determine the impact of these interactions on these cells. This approach is now a feature of several of the major pharmaceutical companies’ internal activities and interest in this area is growing rapidly.
e-Therapeutics is based in the UK and India, with links to other companies and organisations across North America and South East Asia. For more information, please visit http://www.etherapeutics.co.uk.
Melanie Toyne Sewell
Head of Financial PR, College Hill Life Sciences
D: +44 (0) 207 457 2029
M: +44 (0) 7890 022 814